Top Democrats on multiple House committees joined Wednesday to propose legislation that would expand the number of drugs subject to government price negotiations, even as Medicare faces several court challenges from the pharmaceutical industry.
The bill (H.R. 4895) would increase the number of drugs subject to Medicare negotiation each year from 20 to 50 starting in 2029, according to details released by the House Ways and Means Committee. Democrats from the Energy and Commerce Committee and the Education and the Workforce Committee also backed the proposal, which would also require drug manufacturers to offer the price negotiated with ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.